The current state of artificial intelligence (AI)-based dermatology mobile applications (apps) may be unsafe and ineffective for users, according to a recent study published by Wongvibulsin et al in JAMA Dermatology. Advances in technology have led to the development of many new direct-to-consumer mobile apps offering medical advice for patients with dermatologic diseases. However, these tools may not provide their users with credible information. Investigators systematically searched the Apple and Android mobile app stores and identified 41 AI-based dermatology apps. The investigators then reviewed the apps based on purpose, target audience, evidence-based claims, algorithm details, regulatory status, data availability, dermatologist input, use of image data, and data usage privacy policies. The investigators noted that none of the apps had been approved by the U.S. Food and Drug Administration. They further deemed many aspects of the apps to be concerning and unsafe—including the lack of supporting evidence to support their efficacy, insufficient input from dermatologists during development, inconsistent validation, lack of transparency in algorithm development, questionable data usage practices, and inadequate user privacy protection. They emphasized that the apps may increase biases and disseminate misleading information. The investigators underscored that it is critical for app developers to address these issues as well as establish evaluation criteria in order to minimize the risks associated with using the apps and provide more accurate, reliable, and standardized information for patients with dermatologic diseases.